Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
3.03
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.76 - 4.67
Open     -
Vol / Avg. 0.00/2.19M
Mkt cap 510.80M
P/E     -
Div/yield     -
EPS -0.24
Shares 158.14M
Beta 2.17
Inst. own 46%
Nov 2, 2015
Q3 2015 Geron Corp Earnings Release (Estimated) Add to calendar
Aug 5, 2015
Q2 2015 Geron Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -3727.49% -3093.67%
Operating margin -3776.49% -3149.35%
EBITD margin - -3145.27%
Return on average assets -23.10% -29.74%
Return on average equity -30.82% -37.45%
Employees 42 -
CDP Score - -

Address

SUITE 2070, 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Officers and directors

Hoyoung Huh Ph.D Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 46
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 65
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Development and Technical Operations
Age: 50
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Business Development and Portfolio and Alliance Management
Age: 51
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Age: 54
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 65
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters